Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.37), $0.10 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $59.88 million versus the consensus estimate of $68.18 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.